Table 1.
Baseline characteristics of the included patients (n = 153).
| Characteristics | Values |
|---|---|
| Age | 68.2 ± 8.4 |
| Sex | |
| Men | 119 (77.8%) |
| Women | 34 (22.2%) |
| Hypertension | 68 (44.4%) |
| Diabetes mellitus | 31 (20.3%) |
| Angiographic characteristics | |
| Classic type leakage (+) | 40 (26.1%) |
| Classic type leakage (-) | 113 (73.9%) |
| Central retinal thickness, µm | 446.9 ± 154.3 |
| ≥ 1 disc area extent of subretinal hemorrhage | 44 (28.8%) |
| Type of anti-VEGF agent used for initial loading injections | |
| Ranibizumab | 17 (11.1%) |
| Aflibercept | 136 (88.9%) |
Data are presented as mean ± standard deviation or number (%) where applicable.
Abbreviations: VEGF, vascular endothelial growth factor.